SCHEMBL7126897

SCHEMBL7126897

c1ccc(Nc2ccc(Nc3ncnc4cc(-c5ccccc5)sc34)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 10/20 1.00
EGFR P00533 12/20 0.77
KDR P35968 2/20 0.67
IKBKB O14920 1/20 0.57
FGFR1 P11362 2/20 0.53
TUBB4A P04350 1/20 0.53
TUBB P07437 1/20 0.53
TUBA3C P0DPH7 1/20 0.53
TUBA1B P68363 1/20 0.53
TUBA4A P68366 1/20 0.53
TUBB4B P68371 1/20 0.53
TUBB3 Q13509 1/20 0.53
TUBB2A Q13885 1/20 0.53
TUBB8 Q3ZCM7 1/20 0.53
TUBA3E Q6PEY2 1/20 0.53
TUBA1A Q71U36 1/20 0.53
TUBA1C Q9BQE3 1/20 0.53
TUBB6 Q9BUF5 1/20 0.53
TUBB2B Q9BVA1 1/20 0.53
TUBB1 Q9H4B7 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13434839 0.97 FLT1 (0.94) FLT1EGFRKDRIKBKBFGFR1
SCHEMBL7123725 0.92 FLT1 (0.85) FLT1EGFRKDRIKBKBFGFR1
SCHEMBL7119409 0.92 FLT1 (0.85) FLT1EGFRKDRIKBKBTUBB4A
SCHEMBL7127028 0.92 FLT1 (0.85) FLT1EGFRKDRIKBKBFGFR1
SCHEMBL7127078 0.92 FLT1 (0.85) FLT1EGFRKDRIKBKBFGFR1
SCHEMBL7123651 0.92 FLT1 (0.84) FLT1EGFRKDRTUBB4ATUBB
SCHEMBL7116894 0.91 FLT1 (1.00) FLT1EGFRKDRIKBKBFGFR1
SCHEMBL27521104 0.91 FLT1 (0.83) FLT1EGFRKDRIKBKBTUBB4A
SCHEMBL7119481 0.89 FLT1 (0.80) FLT1EGFRKDRTUBB4ATUBB
SCHEMBL7125076 0.89 EGFR (0.98) FLT1EGFRKDRIKBKBTUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US claimed
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US disclosed
US-6492383-B1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2002-12-10 US disclosed
EP-1028964-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2000-08-23 EP disclosed
WO-1999024440-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents TYMP, DPYD, HPRT1 FLT1 1043/4885EGFR 2961/4885KDR 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.